Successful treatment of severe lactic acidosis and tumor lysis syndrome related to intravascular lymphoma in the intensive care unit.

We report a rare case in which a patient with intravascular lymphoma involving multiple organ failure survived. PMID: 31308316 [PubMed - as supplied by publisher]
Source: Journal of Nippon Medical School - Category: Universities & Medical Training Authors: Tags: J Nippon Med Sch Source Type: research

Related Links:

MALT lymphoma is an indolent disease with favorable treatment outcomes. There was no significant difference in overall survival between patients treated with and without surgical resection, but surgery still plays an important role in the diagnosis and treatment of MALT. AbstractPrimary pulmonary mucosa ‐associated lymphoid tissue‐derived (MALT) lymphoma is a rare disease with a favorable prognosis. However, its clinical characteristics, diagnosis, treatment, and prognoses remain unclear. We retrospectively analyzed 80 patients with pathologically confirmed MALT lymphoma from 2006 to 2018. The clinical characteristics,...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
We present a case of PTCL, which was misdiagnosed as eosinophilic pneumonitis (EP) based on samples obtained from transbronchial cryobiopsy. To our knowledge, this is the first reported case of PTCL masquerading as EP.
Source: Lung India - Category: Respiratory Medicine Authors: Source Type: research
Authors: Yagi S, Zheng R, Nishiyama S, Kawabata Y, Ise T, Sugiura K, Yoshinari H, Nishisho T, Bando Y, Kagawa K, Fukuda D, Soga T, Saijo Y, Kusunose K, Yamaguchi K, Yamada H, Soeki T, Wakatsuki T, Kawahito S, Akaike M, Sata M Abstract Primary non-Hodgkin bone lymphoma (PBL) can involve solitary or multiple destructive bone lesions such as those of the femur or pelvis humerus, and some cases have osteolytic lesions. PBL is a rare disease in adults. Thus, PBL is rarely considered a differential diagnosis of the osteolytic tumor. In addition, PBL can be underdiagnosed because patients do not experience symptoms or sho...
Source: Journal of Medical Investigation - Category: General Medicine Tags: J Med Invest Source Type: research
Conclusion: Composite lymphomas pose a particular diagnostic challenge, and currently there are no agreed standards for treatment (4). PMID: 31633478 [PubMed - as supplied by publisher]
Source: Cardiovascular and Hematological Disorders Drug Targets - Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research
Venetoclax is a B cell lymphoma 2 (BCL-2) inhibitor active in multiple myeloma, particularly those harboring t(11;14) associated with high BCL-2 expression. Approximately 50% of patients with immunoglobulin light chain (AL) amyloidosis have t (11;14), making venetoclax a suitable agent to consider in this rare disease. We aimed to identify the safety and efficacy of venetoclax in patients with AL amyloidosis.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
Publication date: Available online 28 September 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Zachary L. Quinn, Karam Zakharia, Janet L. Schmid, John J. Schmieg, Hana Safah, Nakhle S. SabaAbstractPrimary dural diffuse large B-cell lymphoma (PD-DLBCL) is a rare and aggressive B-cell non-Hodgkin lymphoma (NHL) that can present in intracranial or intraspinal locations. While the optimal management is unknown, PD-DLBCL therapy is often mirrored after primary central nervous system lymphoma (PCNSL) therapy and aggressive treatment with a high dose Methotrexate (MTX)-based regimen is frequently used. Our comprehen...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
CONCLUSION: This is the first study to examine such a large library of clinically approved compounds for the identification of novel drug candidates for MCL treatment, the results could be rapidly translated into clinical practice in patients with MCL. PMID: 31526347 [PubMed - as supplied by publisher]
Source: Combinatorial Chemistry and High Throughput Screening - Category: Chemistry Authors: Tags: Comb Chem High Throughput Screen Source Type: research
Conclusion: The present study revealed differences in clinicopathological features but similarities in clinical outcomes of MTX-CHL and sporadic CHL.
Source: In Vivo - Category: Research Authors: Tags: Clinical Studies Source Type: research
Authors: Zhao P, Zhou Y, Li J Abstract OBJECTIVE: To retrospectively study the primary laryngeal lymphoma cases in China reported in Chinese-language literature. METHOD: Chinese-language literature was searched for papers on primary laryngeal lymphoma published in the last 25 years. RESULTS: The selected papers comprised a total of 115 cases. The male-to-female ratio was 3.4:1. Non-Hodgkin's lymphoma was the exclusive pathological type. The estimated 3-year, 5-year and 10-year survival rates were 70.9 ± 6.4 per cent, 63.4 ± 7.6 per cent and 56.4 ± 9.5 per cent respectively, as determine...
Source: Journal of Laryngology and Otology - Category: ENT & OMF Tags: J Laryngol Otol Source Type: research
Rationale: Multiple primary central nervous system lymphoma (MPCNSL) is a rare disease with differential diagnosis and treatment. As the underlying pathogenesis is not yet clarified, the early-stage clinical manifestations are occult and atypical. Also, the imaging manifestations are not specific, which is challenging for the clinical diagnosis and treatment. Therefore, additional clinical research is essential to understand the etiology of the disease. Patient concerns: A 63-year-old male patient suffered from MPCNSLs but without typical clinical manifestations. The findings of the imaging examination were as follows...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research
More News: Cancer & Oncology | Chemotherapy | Hospitals | Intensive Care | Lymphoma | Prednisolone | Rare Diseases | Respiratory Medicine | Rituxan | Skin | Skin Biopsy | Tracheostomy | Universities & Medical Training